TGFB1 and hepatocellular carcinoma: Blocking the Smad pathway or disruption of Smad4 inhibited TGF-β–mediated death of Tak1-deficient hepatocytes, as well as spontaneous liver injury, inflammation, fibrosis, and HCC.